Scroll for more

news

featured

Recent

Jun 15, 2017 articles

BenevolentAI: drug research startup goes on hiring spree as UK’s artificial intelligence sector booms

Our founder Ken Mulvany features in an article looking at the UK’s growing performance in AI technology and the investment the country’s industry is attracting. Ken speaks to Bloomberg’s Giles Turner about BenevolentAI's hiring spree and the 50 roles we are looking to fill.

Apr 26, 2017 articles

9 Computational Drug Discovery Startups Using AI

Nanalyze includes BenevolentAI in its round up of computational drug discovery start-ups using AI.

Apr 25, 2017 articles

A British tech unicorn is trying to cure Alzheimer's and ALS with artificial intelligence

Ken Mulvany, is interviewed by Business Insider UK in an article exploring BenevolentAI’s work to develop new drugs for diseases like Alzheimer’s and ALS.

Apr 13, 2017 articles

BenevolentAI to power small molecule drug discovery BenevolentAI to power small molecule drug discovery

This week, Pharmaphorum covered our partnership announcement with MRC Technology. We’ve teamed up with the independent research charity to investigate new small molecule and antibody drug candidates, combining our technology and R&D experience with their expertise.

Mar 20, 2017 articles

BenevolentAI Q&A: Techworld meets Dr Jackie Hunter, CEO of BenevolentBio

An interview with Jackie Hunter, CEO BenevolentBio, the drug discovery arm of BenevolentAI

Mar 16, 2017 articles

Advances in AI and ML are reshaping healthcare

Read more about TechCrunch's article on startups using artificial intelligence and machine learning to improve healthcare.

Mar 14, 2017 articles

Turning rare diseases into efficient targets with AI

The article discusses the rapid transformation of medical research lead by data, artificial intelligence and supercomputers

Feb 21, 2017 articles

Bold claims for AI are hard to compute for economists

The Financial Times takes a look at the work we’re doing at BenevolentAI to “revolutionise medical research” after speaking to Co-Founder and Director, Ken Mulvany.

Jan 6, 2017 articles

BenevolentAI gets The Economist thinking on biology and AI

We met with The Economist to discuss how artificial intelligence (AI) and machine learning is helping to crack and transform the scientific method.